Assessing the introduction of universal varicella vaccination in the Netherlands.

2.50
Hdl Handle:
http://hdl.handle.net/10029/5600
Title:
Assessing the introduction of universal varicella vaccination in the Netherlands.
Authors:
Boot, Hein J; Melker, Hester E de; Stolk, Elly A; Wit, G Ardine de; Kimman, Tjeerd G
Abstract:
Although varicella is seen as a benign disease in the Netherlands, about 40,000 visits to a general practitioner (GP) are made, over 200 hospital admission occur, and 2.3 persons die on average each year. Most of this burden of disease can be prevented by universal varicella childhood vaccination. Ten years after the introduction of the single-shot, single-component varicella childhood vaccination in the USA, a major reduction in hospitalization, mortality, and burden of disease has been reported. Using our recently vaccine evaluation model for the introduction of a new vaccine in our national immunization program, we have analyzed the feasibility of universal varicella vaccination by replacing the measles-mumps-rubella (MMR) vaccine with a measles-mumps-rubella-varicella (MMRV) vaccine. After structuring and reviewing the available data, two major points of uncertainty remain: (1) the influence of universal childhood vaccination on the incidence of zoster later in life; (2) the cost-effectiveness ratio for the Dutch situation. Despite these uncertainties it is clear that universal childhood vaccination will prevent most of the varicella related GP-visits, hospitalizations, and deaths.
Citation:
Vaccine 2006, 24(37-39):6288-99
Issue Date:
11-Sep-2006
URI:
http://hdl.handle.net/10029/5600
DOI:
10.1016/j.vaccine.2006.05.071
PubMed ID:
16790302
Type:
Article
Language:
en
ISSN:
0264-410X
Appears in Collections:
Vaccines and Vaccination

Full metadata record

DC FieldValue Language
dc.contributor.authorBoot, Hein J-
dc.contributor.authorMelker, Hester E de-
dc.contributor.authorStolk, Elly A-
dc.contributor.authorWit, G Ardine de-
dc.contributor.authorKimman, Tjeerd G-
dc.date.accessioned2006-10-26T09:55:12Z-
dc.date.available2006-10-26T09:55:12Z-
dc.date.issued2006-09-11-
dc.identifier.citationVaccine 2006, 24(37-39):6288-99en
dc.identifier.issn0264-410X-
dc.identifier.pmid16790302-
dc.identifier.doi10.1016/j.vaccine.2006.05.071-
dc.identifier.urihttp://hdl.handle.net/10029/5600-
dc.description.abstractAlthough varicella is seen as a benign disease in the Netherlands, about 40,000 visits to a general practitioner (GP) are made, over 200 hospital admission occur, and 2.3 persons die on average each year. Most of this burden of disease can be prevented by universal varicella childhood vaccination. Ten years after the introduction of the single-shot, single-component varicella childhood vaccination in the USA, a major reduction in hospitalization, mortality, and burden of disease has been reported. Using our recently vaccine evaluation model for the introduction of a new vaccine in our national immunization program, we have analyzed the feasibility of universal varicella vaccination by replacing the measles-mumps-rubella (MMR) vaccine with a measles-mumps-rubella-varicella (MMRV) vaccine. After structuring and reviewing the available data, two major points of uncertainty remain: (1) the influence of universal childhood vaccination on the incidence of zoster later in life; (2) the cost-effectiveness ratio for the Dutch situation. Despite these uncertainties it is clear that universal childhood vaccination will prevent most of the varicella related GP-visits, hospitalizations, and deaths.en
dc.format.extent167807 bytes-
dc.format.mimetypeapplication/pdf-
dc.language.isoenen
dc.titleAssessing the introduction of universal varicella vaccination in the Netherlands.en
dc.typeArticleen
dc.format.digYES-
All Items in WARP are protected by copyright, with all rights reserved, unless otherwise indicated.